Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Marsh, Rebecca A  [Clear All Filters]
2024
Grunebaum E, Arnold DE, Logan B, Parikh S, Marsh RA, Griffith LM, Mallhi K, Chellapandian D, Lim SSi, Deal CL, et al. Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: a PIDTC study. J Allergy Clin Immunol. 2024.
2023
Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, et al. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Transplant Cell Ther. 2023.
Böhm S, Wustrau K, Schmid JPachlopnik, Prader S, Ahlman M, Yacobovich J, Beier R, Speckmann C, Behnisch W, Ifversen M, et al. Survival in primary hemophagocytic lymphohistiocytosis 2016-2021: etoposide is better than its reputation. Blood. 2023.
2022
Durkee-Shock J, Zhang A, Liang H, Wright H, Magnusson J, Garabedian E, Marsh RA, Sullivan KE, Keller MD. Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data from the USIDNET Registry. J Allergy Clin Immunol Pract. 2022.
2021
Marsh RA, Hebert K, Kim S, Dvorak CC, Aquino V, K Baker S, Chellapandian D, Saldana BDavila, Duncan C, Eckrich MJ, et al. A Comparison of Hematopoietic Cell Transplant Conditioning Regimens for Hemophagocytic Lymphohistiocytosis Disorders. J Allergy Clin Immunol. 2021.
2020
Lugt MTVander, Chen X, Escolar ML, Carella BA, Barnum JL, Windreich RM, Hill MJ, Poe M, Marsh RA, Stanczak H, et al. Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Adv. 2020;4(13):3041-3052.
2019
Kellner ES, Krupski C, Kuehn HSun, Rosenzweig SD, Yoshida N, Kojima S, Boutbol D, Latour S, Barlogis V, Galambrun C, et al. Allogeneic Hematopoietic Stem Cell Transplant Outcomes for Patients with Dominant-Negative IKFZ1/IKAROS Mutations. J Allergy Clin Immunol. 2019.
2016
Chandrakasan S, Marsh RA, Uzel G, Holland SM, Shah KN, Bleesing J. Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant. J Allergy Clin Immunol. 2016.
Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, El-Bietar J, Chandra S, Davies SM, Bleesing JJ, et al. A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016.
Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O'Brien TA, Mehta PA. A reduced intensity conditioning regimen for patients with Dyskeratosis Congenita undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016.
Khandelwal P, Bleesing JJ, Davies SM, Marsh RA. A Single Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced Intensity Conditioning to Myeloablative Busulfan, Cyclophosphamide, and Anti-Thymocyte Globulin for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2016.
2014
Haines HL, Bleesing JJ, Davies S, Hornung L, Jordan MB, Marsh RA, Filipovich AH. Outcomes of Donor Lymphocyte Infusion for Treatment of Mixed Donor Chimerism Following a Reduced Intensity Preparative Regimen for Pediatric Patients with Non-Malignant Diseases. Biol Blood Marrow Transplant. 2014.